

Anti-bacterial Compounds to Treat Neisseria gonorrhoeae Infections

Track Code: 2020-RAMA-68860

Categories:

- Pharmaceuticals

Keywords:

- Antimicrobial Resistance
- Gonorrhea
- Gram-Negative
- Lactones
- Pharmaceuticals

Purdue University researchers have identified a class of compounds for use in treating gonorrhea infection. Strains of *Neisseria gonorrhoeae*, the bacterial agent responsible for gonorrhea infections, resistant to most contemporarily used antibiotics are becoming more prevalent. This fact has made gonorrhea a national and international health crisis as health agencies around the world consider gonorrhea a serious threat. To make matters even worse, major pharmaceuticals companies often abandon antibiotics research projects due to non-profitability. Thus new compounds have to be identified to combat this gonorrhea superbug.

Researchers at Purdue University identified a class of compounds that kill *Neisseria gonorrhoeae* cells. The researchers screened the most potent compounds against a panel of *Neisseria gonorrhoeae* strains. Three compounds exhibited potent activity against the *Neisseria gonorrhoeae* panel with the most potent having MIC values of 0.25 – 2 micrograms per milliliter. These compounds show promise for treatment of gonorrhea across the world and could help alleviate the growing concern of antimicrobial resistance.

Advantages:

- Novel neisseria gonnorrhea treatment option

Potential Applications:

- Antimicrobial resistance
- Decreasing spread of STDs

People:

- Ramachandran, Padinjaremadhom V (Project leader)
- Seleem, Mohamed

Intellectual Property:

Application Date: March 26, 2021

Type: Provisional-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Application Date: April 9, 2020

Type: Provisional-Patent

Country of Filing: United States

Patent Number: (None)

Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization

The Convergence Center

101 Foundry Drive, Suite 2500

West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: otcip@prf.org